Disease‐Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium
-
- Raymond Evers
- Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co. Kenilworth New Jersey USA
-
- Micheline Piquette‐Miller
- Leslie Dan Faculty of Pharmacy University of Toronto Toronto Ontario Canada
-
- Joseph W. Polli
- Mechanistic Safety and Drug Disposition, GlaxoSmithKline King of Prussia Pennsylvania USA
-
- Frans G.M. Russel
- Department of Pharmacology and Toxicology Radboud University Medical Center Nijmegen The Netherlands
-
- Jason A. Sprowl
- Department of Pharmaceutical Social and Administrative Sciences, School of Pharmacy, D'Youville College School Buffalo New York USA
-
- Kimio Tohyama
- Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Fujisawa Kanagawa Japan
-
- Joseph A. Ware
- Department of Small Molecule Pharmaceutical Sciences Genentech South San Francisco California USA
-
- Saskia N. de Wildt
- Department of Pharmacology and Toxicology and Department of Intensive Care Radboud University Medical Center, Nijmegen, The Netherlands, and Intensive Care and Department of Pediatric Surgery, Erasmus MC Sophia Children's Hospital Rotterdam The Netherlands
-
- Wen Xie
- Center for Pharmacogenetics and Department of Pharmaceutical Sciences, School of Pharmacy University of Pittsburgh Pittsburgh Pennsylvania USA
-
- Kim L.R. Brouwer
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy University of North Carolina Chapel Hill North Carolina USA
Abstract
<jats:p>Drug transporters are critically important for the absorption, distribution, metabolism, and excretion (ADME) of many drugs and endogenous compounds. Therefore, disruption of these pathways by inhibition, induction, genetic polymorphisms, or disease can have profound effects on overall physiology, drug pharmacokinetics, drug efficacy, and toxicity. This white paper provides a review of changes in transporter function associated with acute and chronic disease states, describes regulatory pathways affecting transporter expression, and identifies opportunities to advance the field.</jats:p>
Journal
-
- Clinical Pharmacology & Therapeutics
-
Clinical Pharmacology & Therapeutics 104 (5), 900-915, 2018-07-12
Wiley
- Tweet
Details 詳細情報について
-
- CRID
- 1360011142930769536
-
- DOI
- 10.1002/cpt.1115
-
- ISSN
- 15326535
- 00099236
-
- Data Source
-
- Crossref